Can a burst of radiation make CAR t-cells fight cancer harder?

NCT ID NCT07725406

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether adding a small dose of total body radiation to standard CAR T-cell therapy can help the immune cells grow stronger and last longer in the body. It enrolls adults with relapsed or hard-to-treat diffuse large B-cell lymphoma or multiple myeloma who are already scheduled to receive a commercial CAR T-cell product. The goal is to see if the combination is safe and can improve the cancer-killing response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low-dose total body irradiation added to standard CAR T-cell therapy (CD19 or BCMA-directed)
What this could lead to
If successful, this approach could make CAR T-cell therapy more effective and durable for patients with hard-to-treat blood cancers.
What could go wrong
This is an early-phase, dose-escalation trial with only 32 participants, so safety and effectiveness are not yet established. Adding radiation may increase side effects like cytokine release syndrome or bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Weill Cornell Medicine/NewYork-Presbyterian Hospital

    New York, New York, 10065, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••